CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.
Number of employees : 27 000 people.
2019 2020 Delta AUD (in Million) % AUD (in Million) % CSL Behring 10,268 86.3% 11,715 86.3% +14.1% Seqirus 1,672 14.1% 1,935 14.3% +15.73%
2019 2020 Delta AUD (in Million) % AUD (in Million) % United States 5,557 46.7% 6,859 50.5% +23.44% Rest of World 2,442 20.5% 2,976 21.9% +21.87% Germany 1,068 9% 1,232 9.1% +15.34% Australia 981.89 8.3% 1,122 8.3% +14.29% United Kingdom 713.69 6% 713.33 5.3% -0.05% Switzerland 302.03 2.5% 426.33 3.1% +41.15% China 875.06 7.4% 321.16 2.4% -63.3%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
454,048,707
454,028,492
100.0% 0
0.0% 100.0%
Shareholders CSL Limited (AU000000CSL8) CSL Limited (US)
Name Equities % BlackRock Fund Advisors 14,104,126
3.10% The Vanguard Group, Inc. 12,503,859
2.75% Norges Bank Investment Management 5,469,725
1.20% Vanguard Investments Australia Ltd. 5,139,419
1.13% BlackRock Investment Management (Australia) Ltd. 4,626,484
1.02% Fidelity Management & Research Co. LLC 4,443,707
0.98% WCM Investment Management LLC 4,375,928
0.96% Capital Research & Management Co. (World Investors) 3,987,792
0.88% BlackRock Advisors (UK) Ltd. 3,428,750
0.75% BlackRock Investment Management (UK) Ltd. 3,213,086
0.71%
Name Equities % WCM Investment Management LLC 3,752,309
0.41% Thornburg Investment Management, Inc. 2,388,344
0.26% Parametric Portfolio Associates LLC 1,095,366
0.12% Vontobel Asset Management, Inc. 519,359
0.057% Fisher Asset Management LLC 336,618
0.037% Aperio Group LLC 196,815
0.022% Northern Trust Investments, Inc.(Investment Management) 115,462
0.013% William Blair Investment Management LLC 109,264
0.012% Truist Bank (Private Banking) 104,439
0.011% Equitable Trust Co. 95,744
0.011%
Company contact information
CSL Ltd.
45 Poplar Road
Parkville, Victoria (VIC) 3052
Phone : +61.3.9389.1911
Fax : +61.3.9389.1434
Web :
http://www.csl.com.au
AstraZeneca shares fall on 'hefty' $39-billion Alexion deal
Sector Biopharmaceuticals
1st jan. Capitalization (M$)
CSL LIMITED -5.54% 93 853
SAMSUNG BIOLOGICS CO.,LTD. -2.66% 48 243
BIOGEN INC. 12.65% 42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD. -2.71% 35 533
ALEXION PHARMACEUTICALS, INC. 0.26% 34 293
CELLTRION HEALTHCARE CO LTD --.--% 19 919
UCB 2.79% 19 838
GRIFOLS, S.A. 1.05% 17 400
INNOVENT BIOLOGICS, INC. 10.48% 16 410
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. -13.52% 15 907
BIOMARIN PHARMACEUTICAL INC. -5.38% 15 062
ZAI LAB LIMITED 26.27% 15 043
BLOE BIOT 0.00% 11 431
CANSINO BIOLOGICS INC. 32.69% 10 547
SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 11.62% 9 797
TWIST BIOSCIENCE CORPORATION 28.35% 8 817
BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. -1.44% 7 957
ZHEJIANG WOLWO BIO-PHARMACEUTICAL CO., LTD. -9.31% 5 621
ABCAM PLC 9.94% 5 240
CHEMOCENTRYX, INC. 0.16% 4 292
APELLIS PHARMACEUTICALS, INC. -8.39% 3 969
Connections : CSL Limited
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
